$218 Million is the total value of Caligan Partners LP's 13 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 30.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LQDA | LIQUIDIA CORP | $58,604,595 | -19.2% | 9,243,627 | 0.0% | 26.91% | -34.0% | |
| Buy | ALIMERA SCIENCES INC | $52,188,977 | +3633.0% | 16,835,154 | +3416.3% | 23.97% | +2949.2% | |
| INTERCEPT PHARMACEUTICALS INCput | $22,248,000 | +67.6% | 1,200,000 | 0.0% | 10.22% | +36.9% | ||
| FLDM | Sell | STANDARD BIOTOOLS INC | $22,104,998 | +35.3% | 7,622,413 | -10.0% | 10.15% | +10.4% |
| ANIK | Buy | ANIKA THERAPEUTICS INC | $20,145,737 | +7.7% | 1,081,360 | +50.1% | 9.25% | -12.1% |
| EXEL | EXELIXIS INC | $19,899,451 | +14.3% | 910,730 | 0.0% | 9.14% | -6.6% | |
| EOLS | Sell | EVOLUS INC | $15,390,261 | +20.3% | 1,683,836 | -4.3% | 7.07% | -1.8% |
| VRNA | VERONA PHARMA PLCsponsored ads | $2,983,943 | -22.9% | 183,064 | 0.0% | 1.37% | -37.0% | |
| ADMA | Sell | ADMA BIOLOGICS INC | $2,139,097 | -31.6% | 597,513 | -29.5% | 0.98% | -44.2% |
| VRCA | New | VERRICA PHARMACEUTICALS INC | $1,009,817 | – | 259,593 | +100.0% | 0.46% | – |
| REPH | Buy | SOCIETAL CDMO INC | $794,191 | -33.0% | 1,689,768 | +56.9% | 0.36% | -45.2% |
| YMAB | New | Y-MABS THERAPEUTICS INC | $127,099 | – | 23,321 | +100.0% | 0.06% | – |
| AGIO | AGIOS PHARMACEUTICALS INC | $119,617 | -12.6% | 4,833 | 0.0% | 0.06% | -28.6% | |
| EYPT | Exit | EYEPOINT PHARMACEUTICALS INC | $0 | – | -310,298 | -100.0% | -1.52% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS INC | $0 | – | -1,293,510 | -100.0% | -8.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LIQUIDIA CORP | 4 | Q3 2023 | 49.0% |
| ANIKA THERAPEUTICS INC | 4 | Q3 2023 | 14.6% |
| STANDARD BIOTOOLS INC | 4 | Q3 2023 | 11.7% |
| EVOLUS INC | 4 | Q3 2023 | 10.9% |
| ALIMERA SCIENCES INC | 4 | Q3 2023 | 24.0% |
| ADMA BIOLOGICS INC | 4 | Q3 2023 | 8.6% |
| VERONA PHARMA PLC | 4 | Q3 2023 | 4.0% |
| SOCIETAL CDMO INC | 4 | Q3 2023 | 2.0% |
| AGIOS PHARMACEUTICALS INC | 4 | Q3 2023 | 0.1% |
| EXELIXIS INC | 3 | Q3 2023 | 11.5% |
View Caligan Partners LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ALIMERA SCIENCES INC | August 03, 2023 | 17,635,154 | 33.1% |
| EXELIXIS, INC. | June 02, 2023 | 910,730 | 0.3% |
| ADMA BIOLOGICS, INC. | December 09, 2022 | 10,264,311 | 4.6% |
| AMAG PHARMACEUTICALS, INC. | November 16, 2020 | ? | ? |
| Knowles Corp | September 30, 2019 | 102,674 | 0.0% |
View Caligan Partners LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-06 |
| 4 | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13D/A | 2024-01-08 |
| 4 | 2023-12-14 |
| SC 13D/A | 2023-12-14 |
| 4 | 2023-11-29 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| SC 13D/A | 2023-09-11 |
View Caligan Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.